COMPLEMENT 3 GLOMERULONEPHRITIS
Clinical trials for COMPLEMENT 3 GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new COMPLEMENT 3 GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney diseases: early access drug available
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that cause protein in the urine and kidney damage. Participants must have active disease and limited response to other treatments. The …
Matched conditions: COMPLEMENT 3 GLOMERULONEPHRITIS
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:14 UTC
-
New hope for rare kidney patients: Long-Term drug trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called pegcetacoplan for people with two rare kidney diseases: C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). About 100 adults who already completed a one-year stu…
Matched conditions: COMPLEMENT 3 GLOMERULONEPHRITIS
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC